Key Highlights
- Third quarter net loss widened to USD 30.1 million, or USD 1.02 per share, versus USD 0.44 a year ago.
- The loss compared with an estimated USD 0.24 per share and included a USD 20.0 million upfront payment to Haisco.
- Cash reached USD 140.7 million from USD 31.6 million, with a runway projected into the second half of 2029.
- Ciprocfeltin gained its first Marketing approval in China in July, and a second application there is under review.
Nuvectis Pharma (NASDAQ:NVCT) reported a third quarter net loss of USD 30.1 million, or USD 1.02 per share, compared with a loss of USD 7.5 million, or USD 0.44, a year earlier and an estimated loss of USD 0.24 per share. The pre-revenue company recorded no sales. The period followed its June licensing agreement with Haisco for ex-China rights to two drug candidates, and chairman and chief executive Ron Bentsur described the quarter as transformational.
What Drove the Wider Loss
Research and development expense rose to USD 27.4 million from USD 5.8 million, mainly because the USD 20.0 million one-time upfront payment to Haisco was recorded as an expense. General and administrative expense increased to USD 3.7 million from USD 2.0 million, producing an operating loss of USD 31.0 million versus USD 7.8 million. Finance income rose to USD 1.0 million from USD 0.3 million, and weighted shares increased to 29.5 million from 22.7 million. Management said the net loss excluding the upfront payment, a milestone tied to NXP-900 and non-cash Stock Compensation was USD 5.8 million. For nine months, the net loss was USD 43.1 million, or USD 1.69 per share.
Under the Haisco agreement, the company is also liable for up to about USD 1.4 billion in contingent development, regulatory and commercial milestones, plus tiered royalties of 9% to 14% on net sales.
Pipeline Milestones
Ciprocfeltin, also called NXP-100, is a once-daily oral complement Factor B inhibitor. It received its first marketing approval in China in July for patients with paroxysmal nocturnal hemoglobinuria who had not received complement inhibitors, based on a phase 3 study showing superiority over an approved comparator. A second Chinese application, for patients previously treated with C5 inhibitors, is under review, with approval targeted for the first quarter of 2027. Haisco is running a phase 3 study in IgA nephropathy and a phase 2 study in lupus nephritis in China.
NXP-200, an oral brain-penetrant BRAF inhibitor, received breakthrough designation in China in September for BRAF V600 mutant recurrent or progressive high-grade glioma. In a 27-patient phase 1b study presented in October, the response rate was 40% in the 20-patient high-grade glioma cohort, including three complete responses, and 42.9% in the low-grade glioma cohort.
Cash Position and Near-Term Targets
Cash and equivalents were USD 140.7 million at September 30, up from USD 31.6 million at year end, after a July public offering that raised USD 106.8 million net and at-the-market sales that raised USD 38.3 million net. Management projects that this funds operations into the second half of 2029.
Management scheduled several items by year end: an update on the US regulatory path for ciprocfeltin in PNH, an IND filing for another ciprocfeltin indication and a US IND for NXP-200. Further NXP-200 solid tumor data and NXP-900 combination study updates are targeted for early 2027 and the first half of 2027.
Figures Worth Comparing
The quarterly net loss of USD 30.1 million compares with an adjusted loss of USD 5.8 million excluding the license payment, milestone and stock compensation. Cash of USD 140.7 million compares with a nine month net loss of USD 43.1 million. The USD 106.8 million of net offering proceeds compares with the USD 20.0 million upfront payment, and the USD 1.4 billion of contingent milestones compares with the USD 140.7 million of cash on hand.






Please wait processing your request...